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Peter MA Calverley1,2Abstract
Over the last 40 years the assessment and treatment of chronic obstructive pulmonary disease has focused
primarily on airflow obstruction with little significance given to the problem of cough. The reasons for this include
a view that cough arises simply from the direct irritant and inflammatory effect of cigarette smoke or the presence
of excess mucus in the airways. Doubt that cough is of any consequence to patients or responsive to current
therapies has reinforced this opinion. At odds with this is the emerging evidence that cough impacts adversely on
patients’ health status and forms an important component of recently validated quality of life instruments. This
article presents the arguments why the assessment and treatment of cough should have a more prominent place
in the clinical management of COPD.
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Chronic obstructive pulmonary disease (COPD) is now
recognised to be a condition of global importance in
terms of its impact on the morbidity and risk of prema-
ture death of millions of people. The definition of COPD
continues to be refined [1]. However there is general
agreement that this condition results from the interplay
of several respiratory pathologies with emphysema and
respiratory bronchiolitis being the most important which
lead to persistent and usually progressive airflow ob-
struction. This formulation is rather different from the
way in which the same clinical problem was viewed only
40 years ago when a symptomatic definition of chronic
cough and sputum production was the hallmark of an
illness which progressed to disabling breathlessness and
ultimately death from right heat failure (‘blue and
bloated’ bronchitic COPD). The reasons for this change
of emphasis are too complex to explain in detail here
but they undoubtedly led to the clinical significance of
cough as a symptom in COPD being under-appreciated.Correspondence: pmacal@liverpool.ac.uk
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reproduction in any medium, provided the orThe role of cough in COPD has been well reviewed
before [2]. That review was conducted from the perspec-
tive of an expert on cough research but this brief review
takes a slightly different approach seeing cough as one
part of the problems experienced by the COPD patient.
This article will examine whether the currently accepted
view that cough is of little significance in COPD is cor-
rect by considering the arguments put forward by those
sceptical of the relevance of cough to COPD. The out-
come of such an approach may surprise some unfamiliar
with the growing body of literature relevant to this field.‘It’s a smoker’s cough of no great significance’
We do not have good data about the frequency with
which smokers cough. This reflects one of the major
problems in cough research – the lack of simple metrics
which describe coughing. How often should the subject
cough and with what intensity before it is classified as
significant? This Gordian knot was cut by the Medical
Research Council in the 1960’s when they developed an
epidemiological definition of chronic bronchitis [3].
They had previously graded cough as productive or un-
productive and for their definition they focussed on
cough present for at least 3 months of 2 consecutive
years, thereby emphasising chronicity and reasonably. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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out a clinically more severe event. The recognition that
deaths from chronic bronchitis were much more fre-
quent in smokers [4] emphasised the link between bron-
chitis, smoking and adverse outcomes while compelling
data that smoking cessation decreased both bronchitic
symptoms and mortality suggested that the cough was
merely an epiphenomenon and not causally relevant.
This analysis was accepted for much of the last 3 de-
cades but there are now reasons to doubt it. Coughing is
associated with airway inflammation in non-smoking
asthmatics and there are objective data showing persist-
ence of airway inflammation in ex-smoking COPD
patients [5], likely reflecting different mechanisms of in-
flammation at different stages in the evolution of the
pulmonary pathology [6]. Many clinical trials have iden-
tified large numbers so patients with bronchitic symp-
toms as part of their physiologically defined COPD and
in some studies patients have been selected on the basis
of chronic cough being present [7]. While cough dimin-
ishes and even disappears in many ex-smokers this is
not the case in many of those where more severe airflow
obstruction has developed.Cough in COPD is just due to the accumulation of mucus
The epidemiological definition of chronic bronchitis
emphasised the association with sputum production and
it seemed reasonable to assume that excess mucus accu-
mulation was the main factor driving cough in COPD.
This agreed with pathological observation by Reid and
Heard of mucous gland hypertrophy in the centralFigure 1 Capsaicin cough sensitivity in COPD, asthma and healthy su
evoked by that concentration of inhaled capsaicin. Populations reflect healairways of patients dying with what we now term COPD
[8]. Loss of ciliary structure and associated impairments
of muco-ciliary clearance were described in bronchitic
patients as was a favourable effect of beta-agonists in
improving this defect [9]. However other mechanisms
also play a role and there is now evidence for enhanced
non-specific neutrally mediated cough responsiveness in
COPD patients similar to that seen in adult asthmatics
(Figure 1) [10]. These studies used the C5 response to
inhaled capsaicin as their marker of responsiveness ra-
ther than the C2 response where the difference between
patients and control subjects was less evident. These
data have recently been confirmed in a larger study of
healthy subjects, asymptomatic smokers and patients
with moderately severe COPD (Figure 2), [11]. As in the
Liverpool data the C5 rather than the C2 distinguished
between the groups, although here the smokers and
COPD patients showed similarly heightened cough re-
sponses. This suggests that cough reflex sensitivity is en-
hanced in COPD but not to the same degree as is seen
in idiopathic cough and that mucus production which
was not a characteristic of these patients is not always
needed for an abnormal cough response to be present.Self-reported cough is not important to COPD patients
The realisation of the association between self-reported
cough and deaths from bronchitis led to the ‘British hy-
pothesis’ that disease progression in COPD was related
to the presence of bronchitic symptoms. This was tested
in the long term study of lung function, symptoms and
mortality in British postal workers which failed to findbjects. The cumulative frequency of responders defined as 5 coughs
thy normal subjects, and patients with COPD or chronic stable asthma.
Figure 2 Capsaicin cough sensitivity in COPD patients without cough, asymptomatic cougher and healthy subjects. Mean log capsaicin
concentrations in 92 healthy subjects, 68 asymptomatic smokers and 42 COPD patients not complaining of cough. Note that the concentration
required to induce 5 coughs is lower in the COPD patients even though they did not report troublesome cough. The values are similar to those
in the smoking controls and lower than in the healthy subjects.
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[12]. Coupled with the earlier negative studies of chronic
tetracycline treatment in reducing clinical deterioration
in people with more advanced disease, there was a gen-
eral feeling that cough was of little consequence in
COPD. In the manner of the times this decision was
made without asking the patients what they thought.
While there is no doubt that breathlessness is the most
dramatic and disabling symptom experienced by COPD
patients, more recent data shows that cough is also a
matter of concern. Danish data in a large population
study found that the presence of chronic mucous
hypersecretion increased the risk of having pneumonia
and was associated with a faster decline in lung function
in men [13]. More recently workers in Switzerland found
that people with very mild airflow obstruction who had
symptoms, principally cough and sputum production,
showed accelerated decline in lung function over time, a
finding not seen in patients with mild airflow obstruc-
tion who had no symptoms [14].
The impact of cough on patient well being has now
been evaluated. In a telephone survey of 2950 COPD pa-
tients Kessler et al. found that cough was reported by
55% of subjects with 20% rating it severe to extreme
[15]. These symptoms were most evident on rising in
the morning and were more likely to be present then
than at other times of the day. Finally specific questions
about the impact of cough on daily life form a part of
the St Georges Respiratory questionnaire, one of the best
validated health status measurements in the COPD field[16]. Cough is also one of the 8 questions identified as
providing important information independent of the
other domains in the COPD Assessment Test (CAT) an-
other psychometrically validated instrument to assess
disease severity in COPD [17]. Clearly patients find
cough to be an important symptom even if their doctors
are yet to be convinced.
A history of cough provides no clinically useful
information
Cough is now considered, along with breathlessness and
sputum production, to be one of the cardinal symptoms
of COPD [1] and which taken together with exposure to
a suitable risk factor should lead to a diagnostic spirom-
etry test. The presence of cough increases the chances
that a screening spirometry in primary care will be
positive [18]. As noted above a question about cough
(I never cough – I cough all the time) contributes in-
dependently to the CAT score which is now being
widely used to assess the impact of COPD on the pa-
tient’s well being. Exacerbations are key events in the
natural history of COPD and patients who exacerbate
frequently form a discrete phenotype of patient [19].
Several groups have found that the presence of cough
and sputum identifies patients at greater risk of subse-
quent exacerbation as defined by the need for antibi-
otics and/or corticosteroids [20]. Questions about
cough form an important part of the recently validated
EXACT-PRO questionnaire used to monitor patients
for the onset and resolution of these events [21].
Table 1 Adjusted mean scores from daily diary card
recordings of cough (0–3 intensity scale) from the
TRISTAN study (24)




(n = 357) 1.44 −0.091 −0.17, -0.02 0.018
Salmeterol
(n = 370) 1.36 −0.018 −0.09, 0.06 0.639
FP
(n = 368) 1.38 −0.037 −0.11, 0.04 0.340
SFC
(n = 351) 1.35 - - -
Note that not all patients report cough and the scale not being validated for
its measurement properties. Despite this the combination of bronchodilator
and inhaled corticosteroid was associated with significantly less cough during
the one year study period.
FP Fluticasone propionate.
SFC Salmeterol Fluticasone propionate Combination.
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At present it is difficult to quantify the degree to which
cough responds to treatment for COPD. In part this re-
flects the lack of focus on cough in clinical studies where
most attention has been paid to the relief of breathlessness
or the prevention of exacerbations. However the lack of a
validated measure of cough intensity and frequency which
is known to respond to interventions is also a factor. This
situation may improve when newer instruments such as
the CAT and EXACT questionnaires are studied in treat-
ment trials.
There is general agreement that COPD patients who
stop smoking are less likely to report the symptom of
cough although this change may be more evident in the
earlier stages of the disease, when lung function im-
provement with treatment is more evident. The propor-
tion of patients with mild-moderate COPD who report a
chronic cough declines by about 5% over a 5 year follow
up period but only 10% of similar patients who quit
complain of cough 5 years after stopping [22]. Whether
other therapies such as pulmonary rehabilitation influ-
ence cough frequency is not known. Treatment with
non-specific cough suppressants has proven to be disap-
pointing. In a carefully designed cross over study 21
COPD patients received 60 mg oral codeine twice daily
or an identical placebo and assessed at baseline and on
two study days each one week apart. Subjectively
reported cough and objective counts of the number of
coughs and their duration were made together with a
measurement of citric acid induced cough threshold
[23]. Although most patients reported spontaneous im-
provement in their symptoms there were no differences
in the subjective or objective treatment arms of the
study. Uncontrolled observations of capsaicin cough
threshold between patients taking regular Ipratropium
and those not treated with this anticholinergic agent sug-
gested that the cough threshold was lower in the treated
patients [10]. However this may reflect confounding by
treatment indication rather than a true drug effect.
Many pharmaceutical studies of COPD treatment have
recorded cough as a symptom in daily patient diary
cards but have seldom analysed the resulting data. One
example of this is presented in Table 1 which is derived
from the TRISTAN study comparing an inhaled cortico-
steroids, a long-acting beta-agonist, the combination
SFC and placebo in severe COPD patients over one year
[24]. The diary card reported cough on a simple inten-
sity scale and these results make no adjustment for the
number of people in whom the symptom is not
reported. Nonetheless it is clear that patients receiving
treatment reported less cough although the difference
was only statistically significant when both inhaled
corticosteroid and beta-agonist were co-administered.
Given the focus of new anti-inflammatory therapies likeroflumilast on patients who report cough [25] it is to be
hoped that future studies using these agents will deter-
mine whether cough improves with therapy.
In summary it appears that the presence of cough with
or without sputum is an early feature of clinical COPD
that helps identify people at risk of progressive disease.
The cough reflex in COPD is increased to levels seen in
current smokers even when the patient no longer
smokes. Cough remains a key symptom in the diagnosis
of COPD and its presence helps identify those patients
at greatest risk of future exacerbations. Smoking cessa-
tion early in the natural history of the disease remains
the most effective way of reducing cough but other ther-
apies show some promise. Non-specific cough suppres-
sants do not appear effective in COPD and should be
avoided. What is really needed is a more systematic
study of this important symptom in larger numbers of
well characterised patients using validated ways of
assessing the occurrence and impact of cough. Once we
better understand the nature and variability of this
symptom at a patient level then we will be able to de-
velop more effective methods of managing it in clinical
practice.Abbreviations
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